Brokerages Set GRAIL, Inc. (NASDAQ:GRAL) Price Target at $67.78

GRAIL, Inc. (NASDAQ:GRAL) has been given a consensus rating of “Hold” by the ten research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $67.7778.

A number of analysts recently weighed in on GRAL shares. Mizuho upped their target price on shares of GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Robert W. Baird set a $70.00 target price on GRAIL in a research note on Wednesday, May 6th. Piper Sandler raised their price target on shares of GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. Guggenheim dropped their price objective on GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a report on Monday, March 30th. Finally, TD Cowen reiterated a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th.

Insider Buying and Selling

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the sale, the insider directly owned 163,738 shares in the company, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.83% of the company’s stock.

Institutional Investors Weigh In On GRAIL

A number of hedge funds have recently modified their holdings of GRAL. N.E.W. Advisory Services LLC acquired a new stake in GRAIL during the 4th quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd bought a new stake in GRAIL during the 4th quarter worth about $28,000. Elyxium Wealth LLC bought a new stake in GRAIL during the fourth quarter worth about $31,000. Comerica Bank raised its stake in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares in the last quarter. Finally, Fifth Third Bancorp lifted its stake in GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after acquiring an additional 472 shares during the last quarter.

GRAIL Price Performance

NASDAQ GRAL opened at $67.84 on Friday. GRAIL has a 52-week low of $29.95 and a 52-week high of $118.84. The firm has a market capitalization of $2.91 billion, a price-to-earnings ratio of -6.54 and a beta of 3.22. The company’s fifty day moving average is $66.55 and its two-hundred day moving average is $68.77.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, beating the consensus estimate of ($2.76) by $0.47. The firm had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. As a group, sell-side analysts expect that GRAIL will post -10.91 earnings per share for the current fiscal year.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Negative Sentiment: Multiple law firms, including Robbins Geller, Hagens Berman, Rosen, Pomerantz, and others, issued fresh notices on July 24 urging investors who bought GRAIL shares during the May 13, 2025 to February 19, 2026 class period to seek appointment as lead plaintiff before the August 4 deadline. Article Title
• Negative Sentiment: A newly filed securities-fraud lawsuit alleges GRAIL misrepresented results and/or trial details around its cancer screening program, which could raise legal costs and create overhang on the stock. Article Title
• Neutral Sentiment: One update noted short interest at 0 shares, so there is no meaningful short-selling data in the latest report to explain the move. Article Title

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.